Tocqueville Asset Management L.P. reduced its stake in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 31.6% during the third quarter, Holdings Channel.com reports. The firm owned 3,688 shares of the biopharmaceutical company’s stock after selling 1,700 shares during the period. Tocqueville Asset Management L.P.’s holdings in GW Pharmaceuticals PLC- were worth $424,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Kavar Capital Partners LLC bought a new stake in GW Pharmaceuticals PLC- in the second quarter worth about $26,000. Signaturefd LLC raised its position in GW Pharmaceuticals PLC- by 192.5% in the third quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 154 shares in the last quarter. Prestige Wealth Management Group LLC bought a new stake in GW Pharmaceuticals PLC- in the second quarter worth about $28,000. Pathstone Family Office LLC bought a new stake in GW Pharmaceuticals PLC- in the second quarter worth about $29,000. Finally, Valeo Financial Advisors LLC raised its position in GW Pharmaceuticals PLC- by 322.6% in the third quarter. Valeo Financial Advisors LLC now owns 262 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 200 shares in the last quarter. Institutional investors and hedge funds own 82.89% of the company’s stock.

Shares of GWPH opened at $109.04 on Friday. The business’s 50-day moving average price is $123.21 and its 200 day moving average price is $154.46. The stock has a market capitalization of $4.16 billion, a P/E ratio of -10.33 and a beta of 2.28. GW Pharmaceuticals PLC- has a 1-year low of $90.14 and a 1-year high of $196.00. The company has a current ratio of 8.31, a quick ratio of 7.59 and a debt-to-equity ratio of 0.03.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.96. The firm had revenue of $72.04 million for the quarter, compared to analysts’ expectations of $37.28 million. GW Pharmaceuticals PLC- had a negative return on equity of 23.44% and a negative net margin of 26.80%. GW Pharmaceuticals PLC-‘s revenue was up 2096.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.25) EPS. On average, research analysts predict that GW Pharmaceuticals PLC- will post -3.53 earnings per share for the current year.

In other GW Pharmaceuticals PLC- news, insider Douglas B. Snyder sold 5,424 shares of GW Pharmaceuticals PLC- stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $13.04, for a total transaction of $70,728.96. Following the transaction, the insider now owns 73,740 shares of the company’s stock, valued at approximately $961,569.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Douglas B. Snyder sold 3,756 shares of GW Pharmaceuticals PLC- stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $13.88, for a total value of $52,133.28. Following the transaction, the insider now directly owns 79,164 shares in the company, valued at approximately $1,098,796.32. The disclosure for this sale can be found here. Company insiders own 3.60% of the company’s stock.

Several equities research analysts have commented on the stock. ValuEngine upgraded shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Wednesday, September 4th. Morgan Stanley boosted their price target on shares of GW Pharmaceuticals PLC- to $238.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating on shares of GW Pharmaceuticals PLC- in a research note on Friday. Cantor Fitzgerald reissued an “overweight” rating and issued a $174.00 price target on shares of GW Pharmaceuticals PLC- in a research note on Wednesday. Finally, BidaskClub raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $203.83.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: What is a stock portfolio tracker?

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.